Format

Send to

Choose Destination
Lancet Oncol. 2014 May;15(6):e213-22. doi: 10.1016/S1470-2045(14)70109-3. Epub 2014 Apr 11.

Cancer research in India: national priorities, global results.

Author information

1
King's College London, Institute of Cancer Policy, King's Health Partners Cancer Centre, London, UK. Electronic address: richard.sullivan@kcl.ac.uk.
2
Tata Memorial Centre, Mumbai, India.
3
All India Institute of Medical Sciences, New Delhi, India.
4
Cancer Institute Adayar, Chennai, India.
5
Nizam's Institute of Medical Sciences, Hyderabad, India.
6
Postgraduate Institute of Medical Education and Research, Chandigarh, India.
7
Kidwai Memorial, Bangalore, India.
8
St John's Medical College and Hospital, Bangalore, India.
9
King's College London, Institute of Cancer Policy, King's Health Partners Cancer Centre, London, UK.
10
Cipla Palliative Care and Training Centre, Pune, India.
11
Regional Cancer Centre, Bikaner, India.
12
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
13
Regional Cancer Centre, Thiruvananthapuram, India.
14
South Asia Network for Chronic Disease, Public Health Foundation of India, New Delhi, India.
15
Centre for Global Health, National Cancer Institute, New Delhi, India.
16
Centre for Global Health, National Cancer Institute, Bethesda, USA.
17
Amrita Institute of Medical Sciences, Kochi, Kerala, India.

Abstract

Over the past 20 years, cancer research in India has grown in size and impact. Clinicians, scientists, and government and state policy makers in India have championed cancer research, from studies to achieve low-tech, large-scale health outcomes to some of the most advanced areas of fundamental cancer science. In this paper, we frame public policy discussions about cancer with use of an in-depth analysis of research publications from India. Cancer research in India is a complex environment that needs to balance public policy across many competing agendas. We identify major needs across these environments such as those for increased research capacity and training and protected time for clinical researchers; for more support from states and enhanced collaborative funding programmes from government; for development of national infrastructures across a range of domains (ie, clinical trials, tissue banking, registries, etc); and for a streamlined and rational regulatory environment. We also discuss improvements that should be made to translate research into improvements in cancer outcomes and public health.

PMID:
24731887
DOI:
10.1016/S1470-2045(14)70109-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center